JP2024538489A5 - - Google Patents

Info

Publication number
JP2024538489A5
JP2024538489A5 JP2024513941A JP2024513941A JP2024538489A5 JP 2024538489 A5 JP2024538489 A5 JP 2024538489A5 JP 2024513941 A JP2024513941 A JP 2024513941A JP 2024513941 A JP2024513941 A JP 2024513941A JP 2024538489 A5 JP2024538489 A5 JP 2024538489A5
Authority
JP
Japan
Prior art keywords
lipid
mol
diseases
approximately
utr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538489A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/074439 external-priority patent/WO2023031394A1/en
Publication of JP2024538489A publication Critical patent/JP2024538489A/ja
Publication of JP2024538489A5 publication Critical patent/JP2024538489A5/ja
Pending legal-status Critical Current

Links

JP2024513941A 2021-09-03 2022-09-02 核酸を送達するための新規な脂質ナノ粒子 Pending JP2024538489A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP2021074344 2021-09-03
EPPCT/EP2021/074344 2021-09-03
EP2021086516 2021-12-17
EPPCT/EP2021/086516 2021-12-17
EPPCT/EP2022/051320 2022-01-21
EP2022051320 2022-01-21
PCT/EP2022/074439 WO2023031394A1 (en) 2021-09-03 2022-09-02 Novel lipid nanoparticles for delivery of nucleic acids

Publications (2)

Publication Number Publication Date
JP2024538489A JP2024538489A (ja) 2024-10-23
JP2024538489A5 true JP2024538489A5 (enExample) 2026-01-20

Family

ID=99799125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513941A Pending JP2024538489A (ja) 2021-09-03 2022-09-02 核酸を送達するための新規な脂質ナノ粒子

Country Status (9)

Country Link
US (1) US20240398940A1 (enExample)
EP (2) EP4763287A2 (enExample)
JP (1) JP2024538489A (enExample)
KR (1) KR20240049810A (enExample)
AU (2) AU2022336209B2 (enExample)
CA (1) CA3230031A1 (enExample)
IL (1) IL309505A (enExample)
MX (1) MX2024002726A (enExample)
WO (1) WO2023031394A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
CN119095585A (zh) * 2022-12-21 2024-12-06 苏州艾博生物科技有限公司 包含固醇修饰的磷脂的脂质纳米颗粒
KR20260018077A (ko) 2023-05-26 2026-02-06 큐어백 에스이 암 항원
EP4731655A1 (en) 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies
WO2025027060A1 (en) 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
EP4761761A1 (en) 2023-08-16 2026-06-24 CureVac SE Rna conjugates
WO2025075396A1 (ko) * 2023-10-06 2025-04-10 한국과학기술연구원 타겟 핵산 검출물질이 담지된 지질 나노입자 및 이를 이용한 막융합 기반의 타겟 핵산 검출 방법
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025134071A1 (en) 2023-12-22 2025-06-26 Sanofi Malic and glutaric acid based ionizable lipids
WO2025137475A1 (en) * 2023-12-22 2025-06-26 The Methodist Hospital Novel rna-nano based genetic modulation of fibrosis for heart failure
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2026006277A2 (en) 2024-06-25 2026-01-02 Massachusetts Institute Of Technology Viral subunit vaccines
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026029597A1 (ko) * 2024-07-31 2026-02-05 주식회사 메디치바이오 신규한 스테롤 지질 또는 이의 유도체를 함유하는 지질 나노입자 조성물
WO2026053147A1 (en) 2024-09-05 2026-03-12 Sanofi Pasteur Inc. Helper lipids and lnp compositions comprising same
WO2026060137A1 (en) * 2024-09-11 2026-03-19 The University Of North Carolina At Chapel Hill Lipid-polymer conjugates and lipid nanoparticles incorporating the same
WO2026136949A1 (en) 2024-12-19 2026-06-25 Caribou Biosciences, Inc. Cd19-targeting engineered immune cells and related methods
WO2026142992A1 (en) 2024-12-23 2026-07-02 Sanofi Pasteur Inc. Lipid nanoparticle formulations
WO2026165320A1 (en) 2025-01-31 2026-08-06 Sanofi Vaccines US Inc. Morpholino cationic lipids
WO2026165530A1 (en) * 2025-02-03 2026-08-06 Renagade Therapeutics Management Inc. Hydrophilic polymer lipids for use in lipid nanoparticles

Family Cites Families (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
ATE492644T1 (de) 1999-09-09 2011-01-15 Curevac Gmbh Transfer von mrna unter verwendung von polykationischen verbindungen
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
WO2006093252A1 (ja) * 2005-03-04 2006-09-08 The University Of Tokyo 膜アンカー型蛍光プローブ
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
CN106046370A (zh) 2007-02-28 2016-10-26 塞瑞纳治疗公司 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物
US20140011964A1 (en) * 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
WO2009043027A2 (en) 2007-09-27 2009-04-02 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5721441B2 (ja) 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーCurevac Gmbh 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
EP2310440A4 (en) 2008-07-10 2013-06-05 Serina Therapeutics Inc POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US20110313017A1 (en) * 2010-01-13 2011-12-22 Protiva Biotherapeutics, Inc. Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2987915T3 (es) 2010-09-20 2024-11-18 Sirna Therapeutics Inc Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012054365A2 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
ES2660129T3 (es) 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
EP3932947A1 (en) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Methods and compositions for delivering mrna coded antibodies
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
AU2014340149B2 (en) 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
PL3122878T3 (pl) 2014-03-24 2019-06-28 Translate Bio, Inc. TERAPIA mRNA DO LECZENIA CHORÓB OCZU
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
US10071168B2 (en) 2014-07-31 2018-09-11 Serina Therapeutics, Inc. Polyoxazoline antibody drug conjugates
EP3177732A4 (en) 2014-08-08 2018-04-25 ModernaTX, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3188749A4 (en) 2014-09-03 2018-06-13 Moderna Therapeutics, Inc. Tolerogenic compositions and methods
DK3221293T3 (da) 2014-11-18 2023-04-03 Arcturus Therapeutics Inc Ioniserbar kationisk lipid til RNA-afgivelse
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
EP3328439B1 (en) 2015-07-31 2020-04-08 Arcturus Therapeutics, Inc. Multiligand agent for drug delivery
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
US20190054112A1 (en) 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
JP2018530587A (ja) 2015-10-16 2018-10-18 モデルナティエックス インコーポレイテッドModernaTX,Inc. mRNAキャップ類似体およびmRNAキャッピングの方法
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
PE20181531A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacuna del virus herpes simple
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US20180271970A1 (en) 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
EP3159407A1 (en) 2015-10-23 2017-04-26 Silence Therapeutics (London) Ltd Guide rnas, methods and uses
EP3368089B1 (en) 2015-10-26 2025-11-05 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
WO2017106799A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2017223135A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
AU2017296195A1 (en) 2016-07-11 2019-01-24 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
WO2018081638A1 (en) 2016-10-27 2018-05-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
US20180185516A1 (en) 2016-12-09 2018-07-05 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US20200368162A1 (en) 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
WO2018165257A1 (en) 2017-03-07 2018-09-13 Translate Bio, Inc. Polyanionic delivery of nucleic acids
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
MX2019011215A (es) 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
US20200046830A1 (en) 2017-03-30 2020-02-13 The Government Of The United States, As Represented By The Secretary Of The Army Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11015204B2 (en) 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
US11530298B2 (en) 2017-06-12 2022-12-20 Translate Bio, Inc. Poly(phosphoesters) for delivery of nucleic acids
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019040590A1 (en) 2017-08-22 2019-02-28 Translate Bio Ma, Inc. MODULATION OF THE EXPRESSION OF SOLUBLE FAS
BR112020004351A2 (pt) 2017-10-19 2020-09-08 Curevac Ag moléculas de ácido nucleico artificial
MA50522B1 (fr) 2017-10-31 2022-09-30 Astrazeneca Ab 151 85 Soedertaelje Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
WO2019140102A1 (en) 2018-01-10 2019-07-18 Translate Bio Ma, Inc. Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
US11975110B2 (en) 2018-02-02 2024-05-07 Translate Bio, Inc. Cationic polymers
WO2019191780A1 (en) 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
EP3793689A1 (en) 2018-05-15 2021-03-24 Translate Bio, Inc. Subcutaneous delivery of messenger rna
AU2019271215B2 (en) 2018-05-16 2024-09-12 Translate Bio, Inc. Ribose cationic lipids
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
US12076439B2 (en) 2018-05-24 2024-09-03 Translate Bio, Inc. Thioester cationic lipids
AU2019277355A1 (en) 2018-05-30 2020-12-17 Translate Bio, Inc. Phosphoester cationic lipids
CN118436618A (zh) 2018-05-30 2024-08-06 川斯勒佰尔公司 信使rna疫苗及其用途
EP3802507A1 (en) 2018-05-30 2021-04-14 Translate Bio, Inc. Vitamin cationic lipids
MA52762A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques comprenant une fraction stéroïdienne
CN120154736A (zh) 2018-07-27 2025-06-17 塞瑞纳治疗阿拉巴马公司 儿茶酚化合物和水溶性聚合物的可裂解缀合物以及使用它们的治疗方法
JP2022501348A (ja) 2018-09-19 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. ステロール類似体及びその使用
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
KR102860605B1 (ko) 2018-11-09 2025-09-15 트랜슬레이트 바이오 인코포레이티드 에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
WO2020097379A2 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Peg lipidoid compounds
CA3117866A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
EP3880174A2 (en) 2018-11-12 2021-09-22 Translate Bio, Inc. Methods for inducing immune tolerance
US12257305B2 (en) 2018-11-21 2025-03-25 Translate Bio, Inc. Cationic lipid compounds
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
EP3959195B1 (en) 2019-04-22 2023-11-08 Translate Bio, Inc. Thioester cationic lipids
WO2020227085A1 (en) 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
AU2020274758B2 (en) 2019-05-14 2025-05-01 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
EP3976593A1 (en) 2019-05-31 2022-04-06 Translate Bio, Inc. Macrocyclic lipids
EP3986858A1 (en) 2019-06-21 2022-04-27 Translate Bio, Inc. Tricine and citric acid lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
US12485181B2 (en) 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
CA3146369A1 (en) 2019-07-08 2021-01-14 Translate Bio, Inc. Improved mrna-loaded lipid nanoparticles and processes of making the same
AU2020315962B2 (en) 2019-07-23 2026-02-12 Translate Bio, Inc. Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
CA3149386A1 (en) 2019-07-31 2021-02-04 Modernatx, Inc. Compositions and methods for delivery of rna interference agents to immune cells
WO2021026358A1 (en) 2019-08-07 2021-02-11 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
GB2600859B (en) 2019-08-14 2024-04-03 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
IL290766B2 (en) 2019-09-03 2026-03-01 Arcturus Therapeutics Inc Administration of therapeutically active conjugates mediated by asialoglycoprotein receptor
WO2021050986A1 (en) 2019-09-11 2021-03-18 Modernatx, Inc. Lnp-formulated mrna therapeutics and use thereof for treating human subjects
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
CA3154720A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents
CA3162019A1 (en) 2019-12-20 2021-06-24 Gemma NAVARRO Lipid nanoparticles for delivery of nucleic acids
JP2023508881A (ja) 2019-12-20 2023-03-06 トランスレイト バイオ, インコーポレイテッド Mrna担持脂質ナノ粒子を調製する改善されたプロセス
MX2022007756A (es) 2019-12-20 2022-09-27 Translate Bio Inc Suministro rectal de arn mensajero.
DE202021004130U1 (de) 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
CN115667207B (zh) 2020-04-01 2025-09-16 翻译生物公司 基于酚酸脂质的阳离子脂质
WO2021222801A2 (en) 2020-05-01 2021-11-04 Arcturus Therapeutics, Inc. Nucleic acids and methods of treatment for cystic fibrosis
ES3066134T3 (en) 2020-05-14 2026-05-11 Translate Bio Inc Peg lipidoid compounds
JP7873638B2 (ja) 2020-05-15 2026-06-12 トランスレイト バイオ, インコーポレイテッド mRNA送達のための脂質ナノ粒子製剤
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2022173667A1 (en) 2021-02-09 2022-08-18 Serina Therapeutics, Inc. Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids

Similar Documents

Publication Publication Date Title
JP2023507465A5 (enExample)
JP2024534900A5 (enExample)
JP6715325B2 (ja) siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用
Rettig et al. Progress toward in vivo use of siRNAs-II
JP6298039B2 (ja) 人工核酸分子
ES2304529T3 (es) Inmunoestimulacion mediante rna modificado quimicamente.
CN103747805B (zh) 用于治疗、延缓和/或预防人类遗传性疾病如强直性肌营养不良症1型(dm1)的化合物
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
KR20160002848A (ko) 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법
CN108136206A (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
EP4455284A1 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
JP2011507534A (ja) 干渉rnaを使用したポロ様キナーゼ発現のサイレンシング方法
JP7592493B2 (ja) 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
US20220259597A1 (en) Oligonucleotide antagonists for rna guided genome editing
WO2015175545A1 (en) Highly stable biodegradable gene vector platforms for overcoming biological barriers
JP2020503390A (ja) 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法
EP4626400A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
KR102931885B1 (ko) 대식세포 유래 소포로 코팅된 지질 나노입자 및 이의 제조 방법
AU2005229159A1 (en) Therapeutic molecules for modulating stability of VEGF transcripts
KR20250129819A (ko) 핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
Haidar NanoDentistry: Perspectives on the role of NanoBiotechnology in biomaterials, pharmaceutics and BioDental tissue engineering
CN116478962B (zh) 增加共转染mRNA的蛋白表达水平和表达时长的重组基因及其应用
US20260125681A1 (en) DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF
US20260041785A1 (en) Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
TW202609056A (zh) 靶向sod1的寡核苷酸